Bart A Ploeger
Overview
Explore the profile of Bart A Ploeger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
581
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Casanova M, Bautista F, Campbell-Hewson Q, Makin G, Marshall L, Verschuur A, et al.
Clin Cancer Res
. 2023 Aug;
29(21):4341-4351.
PMID: 37606641
Purpose: This phase Ib study defined the safety, MTD, and recommended phase II dose (RP2D) of regorafenib combined with vincristine and irinotecan (VI). Secondary objectives were evaluation of antitumor activity...
2.
Fakih M, Raghav K, Chang D, Larson T, Cohn A, Huyck T, et al.
EClinicalMedicine
. 2023 Apr;
58:101917.
PMID: 37090438
Background: Anti-programmed cell death protein 1 antibodies plus multikinase inhibitors have shown encouraging activity in several tumour types, including colorectal cancer. This study assessed regorafenib plus nivolumab in patients with...
3.
Schultze-Mosgau M, Ploeger B, Frei M, Hochel J, Rottmann A
Clin Pharmacokinet
. 2021 Sep;
61(1):1-16.
PMID: 34569009
Vilaprisan is a highly potent selective progesterone receptor modulator in development for the treatment of symptomatic uterine fibroids and endometriosis. Its pharmacokinetics are characterized by rapid absorption, almost complete bioavailability,...
4.
Sutter G, Frei M, Schultze-Mosgau M, Petersdorf K, Seitz C, Ploeger B
Br J Clin Pharmacol
. 2021 Jul;
88(2):734-741.
PMID: 34327754
Aims: We report population pharmacokinetic (popPK) and exposure-response (E-R) analyses for efficacy (induced amenorrhoea [IA]) and safety (unbound oestradiol [E2] concentrations) of the selective progesterone receptor modulator vilaprisan. Results were...
5.
Geoerger B, Morland B, Jimenez I, Frappaz D, Pearson A, Vassal G, et al.
Eur J Cancer
. 2021 Jun;
153:142-152.
PMID: 34157616
Background: This phase 1 study evaluated safety, pharmacokinetics (PK), maximum tolerated dose (MTD), and antitumour activity of regorafenib in paediatric patients with solid tumours. Patients And Methods: Patients (aged 6...
6.
Keunecke A, Hoefman S, Drenth H, Zisowsky J, Cleton A, Ploeger B
Br J Clin Pharmacol
. 2020 May;
86(12):2362-2376.
PMID: 32358822
Aim: Regorafenib is an oral multikinase inhibitor with clinical efficacy in a range of advanced solid tumours. A population pharmacokinetic (PK) model was developed to evaluate the variability of the...
7.
Grevel J, Jentsch G, Austin R, Prins N, Lettieri J, Mitchell D, et al.
Clin Transl Sci
. 2019 Mar;
12(5):459-469.
PMID: 30920122
Sorafenib is an oral multikinase inhibitor approved for the treatment of differentiated thyroid carcinoma (DTC), renal cell carcinoma, and hepatocellular carcinoma. In the phase III DECISION trial in patients with...
8.
Snelder N, Ploeger B, Luttringer O, Rigel D, Webb R, Feldman D, et al.
J Pharmacol Exp Ther
. 2016 Dec;
360(2):356-367.
PMID: 27934627
Sphingosine 1-phosphate (S1P) receptor agonists are associated with cardiovascular effects in humans. This study aims to develop a systems pharmacology model to identify the site of action (i.e., primary hemodynamic...
9.
Reinecke I, Schultze-Mosgau M, Nave R, Schmitz H, Ploeger B
J Clin Pharmacol
. 2016 Dec;
57(5):640-651.
PMID: 27925651
Pharmacokinetics (PK) of anastrozole (ATZ) and levonorgestrel (LNG) released from an intravaginal ring (IVR) intended to treat endometriosis symptoms were characterized, and the exposure-response relationship focusing on the development of...
10.
Moes D, Press R, Ackaert O, Ploeger B, Bemelman F, Diack C, et al.
Br J Clin Pharmacol
. 2016 Jun;
82(1):227-37.
PMID: 27334415
Aims: This study aimed at identifying pharmacological factors such as pharmacogenetics and drug exposure as new predictive biomarkers for delayed graft function (DGF), acute rejection (AR) and/or subclinical rejection (SCR)....